Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP6 | P55212 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | HCAR3 | P49019 | 11/20 | 0.54 |
| ▸ | APEX1 | P27695 | 1/20 | 0.54 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1483517 | 0.88 | CASP6 (0.66) | CASP6TSHRLMNAHCAR3APEX1 | |
| SCHEMBL30481076 | 0.88 | CASP6 (0.66) | CASP6TSHRLMNAHCAR3APEX1 | |
| SCHEMBL8092214 | 0.87 | CASP6 (0.64) | CASP6TSHRLMNAHCAR3APEX1 | |
| SCHEMBL6341472 | 0.85 | CASP6 (0.66) | CASP6TSHRLMNAHCAR3APEX1 | |
| SCHEMBL20757 | 0.85 | PDK1 (0.68) | CASP6TSHRLMNAHCAR3APEX1 | |
| SCHEMBL18833531 | 0.83 | CASP6 (0.64) | CASP6TSHRLMNAHCAR3APEX1 | |
| SCHEMBL1251308 | 0.83 | CASP6 (0.64) | CASP6TSHRLMNAHCAR3APEX1 | |
| SCHEMBL40979 | 0.83 | CASP6 (0.64) | CASP6TSHRLMNAHCAR3APEX1 | |
| SCHEMBL7402680 | 0.83 | CASP6 (0.58) | CASP6TSHRLMNAHCAR3APEX1 | |
| SCHEMBL6180268 | 0.82 | HCAR3 (0.64) | CASP6TSHRLMNAHCAR3APEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018151678-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-08-23 | — | — | WO | disclosed |
| US-8003228-B2 | Highly photoluminescent organic compounds, synthesis thereof, and use thereof in electroluminescent devices | STMICROELECTRONICS S.R.L. (IT) | 2011-08-23 | — | — | US | disclosed |
| US-8003228-B2 | Highly photoluminescent organic compounds, synthesis thereof, and use thereof in electroluminescent devices | STMICROELECTRONICS S.R.L. (IT) | 2011-08-23 | — | — | US | disclosed |
| US-8003228-B2 | Highly photoluminescent organic compounds, synthesis thereof, and use thereof in electroluminescent devices | STMICROELECTRONICS S.R.L. (IT) | 2011-08-23 | — | — | US | disclosed |
| US-20090322212-A1 | SYNTHESIS OF NEW ORGANIC MATERIAL FOR POLYMERIC LIGHT EMITTING DIODE | STMICROELECTRONICS S.R.L. (IT) | 2009-12-31 | — | — | US | disclosed |
| US-20090322212-A1 | SYNTHESIS OF NEW ORGANIC MATERIAL FOR POLYMERIC LIGHT EMITTING DIODE | STMICROELECTRONICS S.R.L. (IT) | 2009-12-31 | — | — | US | disclosed |
| US-20090322212-A1 | SYNTHESIS OF NEW ORGANIC MATERIAL FOR POLYMERIC LIGHT EMITTING DIODE | STMICROELECTRONICS S.R.L. (IT) | 2009-12-31 | — | — | US | disclosed |
| US-20090105305-A1 | Therapeutic Agents - 550 | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105305-A1 | Therapeutic Agents - 550 | FABP4, GPR119, FASN | CASP6 1602/4885TSHR 4393/4885LMNA 2831/4885 |
| US-20090322212-A1 | SYNTHESIS OF NEW ORGANIC MATERIAL FOR POLYMERIC LIGHT EMITTING DIODE | CCND2, MAP1LC3C, CCNL2 | CASP6 4355/4885TSHR 3941/4885LMNA 849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.